Several platinum complexes have been synthesized in an attempt to find new compounds that show antitumor properties, less severe side effects, and that can overcome cellular resistance. 1 Despite all efforts, only a few compounds have reached clinical use. Among those worth mentioning are the second generation drugs carboplatin which shows less severe nephrotoxicity 3 and oxaliplatin which is active in some resistant cell lines. 4, 5 However, these complexes still present severe side effects and are active in a limited number of tumors. 5, 6 We have recently described the synthesis and characterization of a series of platinum(II) complexes which have as ligands N-benzyl -1,2-ethanediamine and N-benzyl-1,3-propanediamine. 7 Complexes containing diamine ligands have been shown to have relevant antitumor properties 8 and the aromatic compounds could intercalate between the DNA base pairs, 9 possibly increasing their cytotoxic properties. In continuation of the work which has been developed by our research group, we describe in this article the synthesis and characterization of eight new platinum(II) complexes containing ligands derived from 1,2-ethanediamine and 1,3-propanediamine linked to phenylethyl and phenylpropyl groups. In the present work, we also describe the synthesis and characterization of new ligands prepared from 1,4-butanediamine and 1,6-hexanediamine containing phenylethyl and phenylpropyl groups. These ligands will be used in the future preparation of dinuclear platinum complexes.
Ligands 1 to 13 were synthesized by treating the corresponding diamine with an alkyl halide in ethanol. The only exception being compound 11 which was obtained through hydrogenation (H 2 , Pd/C) of compound 9 in methanol (Scheme 1). In the 1 H NMR spectra for all the ligands, signals were observed in the δ 2.50 to 3.48 region corresponding to the methylene hydrogens CH 2 N or CH 2 Ar.
Signals in the δ 6.70 to 8.12 region, attributable to the aromatic ring hydrogens, were also observed. For the others methylene hydrogens one observes signals in the δ 1.20 to 2.05 region. In the 13 C NMR spectra, signals were observed in the δ 18.5 to 52.0 region corresponding to the methylene carbons and signals in the δ 117.2 to 150.1 region attributed to the aromatic carbons.
The platinum(II) complexes (14 to 21) were synthesized by reaction of the corresponding ligands with K2[PtCl4] . For these complexes, one can see in the IR spectra absorptions corresponding to νPt-N and νPt-Cl at 530 and 320 cm −1 , respectively, in addition to the absorptions observed for the ligand. In the 1 H NMR spectra, one observes that the corresponding signals for the hydrogen atoms close to the platinum coordination site result in a more complex splitting pattern compared to the spectra of the free ligands. In the 195 Pt NMR spectra only one signal was observed around δ −2300, which can be anticipated based on data for similar compounds.
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Experimental Section
Compounds a (2-bromoethyl)benzene, b (3-bromopropyl)benzene, and e 1-naphthaleneethanol are commercially available.
Synthesis of intermediates c and d. To nitric acid (7.0 mL) and sulfuric acid (3.5 mL) at 0 o C, the compounds (2-bromoethyl)benzene (6.8 mL; 50 mmol) or (3-bromopropyl)benzene (7.6 mL; 50 mmol) dissolved in dichloromethane were added. The reaction mixtures were stirred for 4 h at room temperature. Water was then added and a liquid/liquid extraction was performed (CH 2 Cl 2 /H 2 O). The organic layer was separated and then evaporated. For compound c, the residue was recrystallized (hexane/ethyl acetate) and then filtered. For compound d, the residue was purified on silica gel, using CCl 4 as eluent. 5, 33.4, 33.8 (CH 2 ), 123.7, 129.4, 146.5, 148.5 (Ph) .
Notes
Synthesis of intermediate f. To 1-naphthaleneethanol (1.72 g; 10 mmol) dissolved in toluene (20 mL), imidazole (1.36 g; 20 mmol), triphenylphosphine (5.24 g; 20 mmol), and iodine (5.08 g; 20 mmol) were added. The reaction mixture was stirred for 12 h under reflux and an extraction (toluene/water) was performed. The organic solvent was evaporated, and the residue was purified on silica gel, using hexane as eluent. 123.0, 125.5, 125.7, 126.2, 126.5; 127.6, 128.9, 131.2, 133.9, 136.7 (napht) .
Synthesis of the ligands (Scheme 1). To a solution of appropriate diamine (100 mmol) in ethanol (30 mL), the corresponding alkyl halide (20 mmol) was slowly added during 4 h. For the 1,2-ethanediamine and 1,3-propanediamine derivatives the reaction mixture was stirred for 48 h at room temperature. In the case of 1,4-butanediamine and 1,6-hexanediamine derivatives the reaction was maintained for 7 days at 60 °C. After which time, the solution was evaporated under reduced pressure, and the residue purified on silica gel 60 G (0.2-0.5 mm), using dichloromethane/methanol 9 : 1 as eluent.
Ligand 11 (Scheme 1) was obtained from the catalytic reduction (H 2 , Pd/C 10%) of 0.580 g (2 mmol) of compound 9 dissolved in methanol (5 mL). The reaction was maintained under a hydrogen atmosphere with stirring for 48 hours at room temperature. The reaction mixture was then filtered and the solvent was evaporated. The residue was purified on silica gel 60 G (0.2-0.5 mm), using dichloromethane/methanol 9 : 1 as eluent. 4, 31.6, 33.8, 42.0, 49.5, 49.8, 50.4 (CH2), 125.9, 128.5, 142.1 (Ph ): 3320, 3290, 3019, 2928, 2855, 1576, 1510, 1454, 1320, 1312, 1119, 747, 699, 550; 1 H NMR (300 MHz, CDCl3): δ 1.30, 1.50, 1.90 (3m, 12H, CH2, NH 2 ), 2.57 (m, 8H, CH 2 ), 7.21 (m, 5H, Ph). 13 C NMR (75 MHz, CDCl 3 ): δ 18. 5, 26.9, 27.3, 30.1, 31.7, 33.7, 33.8, 42.2, 49.6, 50 .0 (CH 2 ), 125.9, 128.4, 142.2 (Ph). δ 2.05 (m, 2H, CH 2 ), 2.85 (t, 2H, CH 2 , J 7.5), 3.07 (t, 2H, CH 2 , J 7.5), 3.27 (m, 4H, CH 2 ), 7.47, 8.12 (2d, 4H, Ph, J 8.8); 13 C NMR (300 MHz, CD 3 OD): δ 29. 2, 33.6, 37.5, 46.2, 49.2 (CH 2 ), 124.9, 130.9, 148.0, 150.1 (Ph) . Yield: 0.26 g, 50%; oil; Anal. (Found: C, 46.35; H, 7.01; N, 16.33. Calc. for C10H17N3.HBr: C, 46.15; H, 6.92; N, 16.15%) ; IR νmax KBr (cm −1 ): 3410, 3310, 3010, 2926, 2852, 1615, 1517, 1376, 1122, 1073, 744; 1 H NMR (300 MHz, CD3OD): δ 2.85 (t, 2H, CH2, J 7.3), 3.12 (m, 4H, CH2), 3.48 (t, 2H, CH2), 6.70, 7.00 (2d, 4H, Ph, J 8.4 ); 13 C NMR (300 MHz, CD3OD): δ 32. 8, 37.3, 49.1, 50.6 (CH2), 117.2, 127.0, 130.6, 147.9 (Ph) .
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12. Yield: 3.93 g, 58%; Anal. (Found: C, 48.95; H, 5.39; N, 8.01. Calc. for C14H18N2.HI: C, 49.12; H, 5.55; N, 8.18%) ; IR νmax KBr (cm ): 3224, 3064, 2944, 2851, 1597, 1496, 1110, 1023, 768; 1 H NMR (300 MHz, D2O): δ 2.90 (m, 2H, CH2), 2.98 (m, 2H, CH2), 3.03 (m, 2H, CH2), 3.29 (m, 2H, CH2), 4H, napht), 7.79, 7.90, 8.03 (3dd, 3H, napht) ; 13 C NMR (75 MHz, D2O): δ 31. 5, 38.3, 47.0, 49.0 (CH2), 123.9, 126.3, 126.6, 127.0, 127.6, 127.9, 129.3, 131.7, 134.2, 134.9 (napht 5, 31.5, 33.6, 42.1, 49.8, 50.5 (CH2), 123.9, 125.7, 126.1, 126.8, 127.2, 129.0 (napht) .
Synthesis of the complexes (Scheme 1).
To a solution of K2[PtCl4] (0.415 g; 1 mmol) in water (10 mL), the appropriate ligand (1 mmol), dissolved in water (5 mL), was added slowly with stirring. After 24 h at room temperature, the solid that formed was filtered off, washed with water, and dried.
14. Yield: 0.34 g, 80%; yellow solid, m.p.: 296-300 °C (dec); Anal. (Found: C, 27.45; H, 3.65; N, 6.22; Cl, 16.10. Calc. for C10H16N2Cl2Pt: C, 27.90; H, 3.72; N, 6.51; Cl, 16 ): 3244, 3195, 3133, 3026, 2926, 1603, 1453, 1285, 752, 699, 540, 
